Bristol Myers Squibb Sees Positive Results for Breyanzi in Lymphoma Trials

Dow Jones

Feb 10, 2025

By Adriano Marchese

Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat.

The biopharmaceutical company said Monday that the second phase of its Transcend FL trial for the drug Breyanzi met its primary endpoint. The treatment aims to treat patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

Indolent lymphomas are a rare type of lymphoma that tend to grow more slowly and have fewer signs and symptoms when first diagnosed.

Results showed Breyanzi, also known as lisocabtagene maraleucel, showed a statistically significant and clinically meaningful overall response rate in its patients.

According to the trial results, Breyanzi showed its ability to continue to provide a durable response and a consistent safety profile with no new safety signals.

The study also met the key secondary endpoint of complete response rate.

Bristol Myers Squibb said this study marks the fifth cancer type in which Breyanzi has demonstrated a clinically meaningful benefit.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

February 10, 2025 08:04 ET (13:04 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2510852314"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510852314\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510852314?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-10 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510852314","market":"hk","top_or_hot":-1,"title":"Bristol Myers Squibb Sees Positive Results for Breyanzi in Lymphoma Trials","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat. \n</p>\n<p>\n  The biopharmaceutical company said Monday that the second phase of its Transcend FL trial for the drug Breyanzi met its primary endpoint. The treatment aims to treat patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma. \n</p>\n<p>\n  Indolent lymphomas are a rare type of lymphoma that tend to grow more slowly and have fewer signs and symptoms when first diagnosed. \n</p>\n<p>\n  Results showed Breyanzi, also known as lisocabtagene maraleucel, showed a statistically significant and clinically meaningful overall response rate in its patients. \n</p>\n<p>\n  According to the trial results, Breyanzi showed its ability to continue to provide a durable response and a consistent safety profile with no new safety signals. \n</p>\n<p>\n  The study also met the key secondary endpoint of complete response rate. \n</p>\n<p>\n  Bristol Myers Squibb said this study marks the fifth cancer type in which Breyanzi has demonstrated a clinically meaningful benefit. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 10, 2025 08:04 ET (13:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Squibb Sees Positive Results for Breyanzi in Lymphoma Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Squibb Sees Positive Results for Breyanzi in Lymphoma Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-10 21:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat. \n</p>\n<p>\n  The biopharmaceutical company said Monday that the second phase of its Transcend FL trial for the drug Breyanzi met its primary endpoint. The treatment aims to treat patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma. \n</p>\n<p>\n  Indolent lymphomas are a rare type of lymphoma that tend to grow more slowly and have fewer signs and symptoms when first diagnosed. \n</p>\n<p>\n  Results showed Breyanzi, also known as lisocabtagene maraleucel, showed a statistically significant and clinically meaningful overall response rate in its patients. \n</p>\n<p>\n  According to the trial results, Breyanzi showed its ability to continue to provide a durable response and a consistent safety profile with no new safety signals. \n</p>\n<p>\n  The study also met the key secondary endpoint of complete response rate. \n</p>\n<p>\n  Bristol Myers Squibb said this study marks the fifth cancer type in which Breyanzi has demonstrated a clinically meaningful benefit. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 10, 2025 08:04 ET (13:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1868836914.USD","symbol_name":"CT (LUX) I AMERICAN \"3\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2510852314","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510852314","pubTimestamp":1739192640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat.The biopharmaceutical company said Monday that the second phase of its Transcend FL trial for the drug Breyanzi met its primary endpoint. The treatment aims to treat patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.Indolent lymphomas are a rare type of lymphoma that tend to grow more slowly and have fewer signs and symptoms when first diagnosed.Results showed Breyanzi, also known as lisocabtagene maraleucel, showed a statistically significant and clinically meaningful overall response rate in its patients.According to the trial results, Breyanzi showed its ability to continue to provide a durable response and a consistent safety profile with no new safety signals.The study also met the key secondary endpoint of complete response rate.Bristol Myers Squibb said this study marks the fifth cancer type in whic","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4126":"金属与玻璃容器","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","BK4559":"巴菲特持仓","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","BK4588":"碎股","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4585":"ETF&股票定投概念","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4581":"高盛持仓","BK4534":"瑞士信贷持仓","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BMY":"施贵宝","LU0237698245.USD":"富达环球地产基金A","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","MYE":"Myers Industries Inc","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC"},"translate_title":"百时美施贵宝在淋巴瘤试验中看到Breyanzi的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1,"MYE":1},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat. \n\n\n  The biopharmaceutical company said Monday that the second phase of its Transcend FL trial for the drug Breyanzi met its primary endpoint. The treatment aims to treat patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma. \n\n\n  Indolent lymphomas are a rare type of lymphoma that tend to grow more slowly and have fewer signs and symptoms when first diagnosed. \n\n\n  Results showed Breyanzi, also known as lisocabtagene maraleucel, showed a statistically significant and clinically meaningful overall response rate in its patients. \n\n\n  According to the trial results, Breyanzi showed its ability to continue to provide a durable response and a consistent safety profile with no new safety signals. \n\n\n  The study also met the key secondary endpoint of complete response rate. \n\n\n  Bristol Myers Squibb said this study marks the fifth cancer type in which Breyanzi has demonstrated a clinically meaningful benefit. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2025 08:04 ET (13:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}